Biotechnology · Healthcare
CFO
2024-05-07–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Stoke Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get STOK alertsThomas Leggett is recorded as CFO at Stoke Therapeutics, Inc. (STOK) since May 7, 2024. Stoke Therapeutics, Inc. reported in an 8-K filed April 29, 2024 that Thomas Leggett was appointed Chief Financial Officer, effective May 7, 2024. The proxy statement of Stoke Therapeutics, Inc. reports total compensation of $1,830,375 for Thomas Leggett in fiscal 2025, including a base salary of $496,375. Disclosed compensation is on record for 2 fiscal years. Thomas Leggett has spoken on 1 earnings call across 1 company, most recently for Stoke Therapeutics, Inc. on August 3, 2026. Stoke Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Stoke Therapeutics, Inc. includes Ian F. Smith (CEO and Board Member), Arthur Tzianabos (Chairman), Thomas E. Leggett (CFO) and 5 others.
“On April 29, 2024, Stoke Therapeutics, Inc. (the "Company") announced that the Board of Directors of the Company (the "Board") appointed Thomas Leggett as the Chief Financial Officer of the Company, including as the "principal financial officer" and "principal accounting officer" of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of May 7, 2024 (the "Appointment Date").”
“Good evening and welcome to Stoke Therapeutics Second Quarter 2026 Business Update Conference Call. I'm Thomas Leggett, the Chief Financial Officer of Stoke Therapeutics.”
2024-05-07–present
Biotechnology · Healthcare
CFO
2024-05-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Stoke Therapeutics, Inc. (STOK) | Chief Financial Officer | $496,375 | $1,830,375 |
| 2024 | Stoke Therapeutics, Inc. (STOK) | Chief Financial Officer | $309,470 | $4,520,386 |